AIM
TNDM icon

Acrospire Investment Management’s Tandem Diabetes Care TNDM Stock Holding History

Acrospire Investment Management’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-33
Closed – – 2534
2017
Q1 		$0 Buy
+33
New +$721 ﹤0.01% 2493

Other funds holding TNDM

FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acrospire Investment Management's TNDM Position: Q2 2017 in Review

Acrospire Investment Management sold out of Tandem Diabetes Care (TNDM) in Q2 2017, closing a stake of 33 shares.

Acrospire Investment Management first reported a position in TNDM in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 63 funds tracked by Wall St. Rank hold TNDM as of Q2 2017.

  • Acrospire Investment Management reported no remaining Tandem Diabetes Care position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 33 Tandem Diabetes Care shares in Q2 2017.
  • Acrospire Investment Management first reported a position in Tandem Diabetes Care in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Tandem Diabetes Care position peaked at $0 in Q1 2017.
  • 63 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.